Atea Pharmaceuticals Inc [NASDAQ: AVIR] traded at a low on 2025-08-29, posting a -3.17 loss after which it closed the day’ session at $3.36.
The results of the trading session contributed to over 161155 shares changing hands. Over the past one week, the price volatility of Atea Pharmaceuticals Inc stands at 4.11% while the volatility over the past one month is 4.11%.
The market cap for AVIR stock reached $266.64 million, with 81.14 million shares outstanding and 64.31 million shares in the current float. Compared to the average trading volume of 393.97K shares, AVIR reached a trading volume of 161155 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atea Pharmaceuticals Inc [AVIR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVIR shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVIR stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Atea Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on August 13, 2024. The new note on the price target was released on August 10, 2023, representing the official price target for Atea Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $14 to $7, while Morgan Stanley kept a Underweight rating on AVIR stock.
The Price to Book ratio for the last quarter was 0.75, with the Price to Cash per share for the same quarter was set at 4.78.
How has AVIR stock performed recently?
Atea Pharmaceuticals Inc [AVIR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.20. With this latest performance, AVIR shares dropped by -7.69% in over the last four-week period, additionally plugging by 10.89% over the last 6 months – not to mention a rise of 0.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVIR stock in for the last two-week period is set at 38.98, with the RSI for the last a single of trading hit 0.15, and the three-weeks RSI is set at 0.15 for Atea Pharmaceuticals Inc [AVIR]. The present Moving Average for the last 50 days of trading for this stock 3.56, while it was recorded at 3.55 for the last single week of trading, and 3.19 for the last 200 days.
Atea Pharmaceuticals Inc (AVIR) Capital Structure & Debt Analysis
According to recent financial data for Atea Pharmaceuticals Inc. ( AVIR), the Return on Equity (ROE) stands at -32.38%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -30.18%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Atea Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -37.31%, showcasing its effectiveness in deploying capital for earnings.
Atea Pharmaceuticals Inc (AVIR) Efficiency & Liquidity Metrics
Based on Atea Pharmaceuticals Inc’s (AVIR) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Atea Pharmaceuticals Inc (AVIR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Atea Pharmaceuticals Inc. (AVIR) effectively leverages its workforce, generating an average of -$2430892.86 per employee. The company’s liquidity position is robust, with a Current Ratio of 19.17% and a Quick Ratio of 19.17%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Atea Pharmaceuticals Inc [AVIR]
With the latest financial reports released by the company, Atea Pharmaceuticals Inc posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVIR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Atea Pharmaceuticals Inc go to 13.82%.
Insider trade positions for Atea Pharmaceuticals Inc [AVIR]
There are presently around $71.89%, or 82.37%% of AVIR stock, in the hands of institutional investors. The top three institutional holders of AVIR stocks are: BLACKROCK INC. with ownership of 9.12 million shares, which is approximately 10.8251%. FMR LLC, holding 6.44 million shares of the stock with an approximate value of $$21.3 million in AVIR stocks shares; and FMR LLC, currently with $$21.1 million in AVIR stock with ownership which is approximately 7.5672%.
